Alpha-1 kinase (ALPK1) has been reported as a potential causative gene for ROSAH Syndrome.
Genetic variants including T237M have been found in ROSAH Syndrome patients. Our in-house study has found that T237M mutation leads to hyperactivity of ALPK1, which may be the cause of the inflammatory syndromes found in ROSAH Syndrome patients. We hypothesize that T237M mutation ALPK1 cause ROSAH Syndrome and an ALPK1 inhibitor can be a potential therapy for treating this disease. To test our hypothesis, we designed an experiment in which ex vivo peripheral blood mononuclear cells (PBMCs) from ROSAH Syndrome patients will be exposed to a potent ALPK1 inhibitor (DF-003) or placebo. We expect to see downregulation of activated inflammatory genes, chemokine/cytokines and acute phase proteins in the ROSAH Syndrome patient samples that are exposed DF-003.
Male or female aged over 18
Patient with ROSAH syndrome with the confirm T237M mutation
person under legal protection or under protectives measures
person unable to express consent
person in emergency situation (vital or not)
person infected by Human Immunodeficiency Virus and/or Hepatitis B Virus and/or Hepatitis C Virus
This study concerns adult subjects with ROSAH syndrome
Cohort
Prospective
Adult subjects with ROSAH syndrome
Other interventionThe main objective is to evaluate the ex vivo inhibitory potential of DF-003 on alpha-1 kinase activity.
Cytokine release assays
The Cytokine release assays will analyzed by ELISA in cells supernatants the Interleukin 8 (IL-8), Tumor Necrosis Factor (TNF) concentrations in the presence/absence of DF-003 and control.
Click on the lead sponsor to view all of their trials.
